Literatuur
- Rose et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. Journal of Clinical Oncology 2007 volume 25 number 19
- Hogberg T et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer - results from two randomised studies. Eur J Cancer 2010 September; 46(13):2422–2431
- Galaal K et al. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database of Systematic Reviews 2014 (5):CD010681
- De Boer S Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol 2019; 20:1273-85
- Thigpen J et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrials carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol. 1999 jun; 17(6):1736-44
- Colombo A et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer. Diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016. Jan; 26(1):2-30
- Van Weelden WJ et al. Anti-estrogen treatment in endometrial cancer. A systematic review. Front Oncol. 2019 may 7;9:359
- Vandenput I et al. Weekly paclitaxel-carboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma. Int J Gynecol Cancer 2012 May; 22(4):617-22
- Miller et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase III trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 nov 20; 38(33):3841-3580
Commissie BOM adviezen
Ga naar de commissie BOM adviezen over endometriumcarcinoom.
Richtlijnen
Ga naar de richtlijn Endometriumcarcinoom in de FMS richtlijnendatabase.